Xilio Therapeutics, Inc. (XLO)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 6 | 44 | 64 | 40 |
| Operating profit | $m | -42 | -31 | ||||||
| Net profit | $m | -55 | -76 | -88 | -76 | -58 | -35 | -22 | - |
| EPS reported | $ | -4.19 | -1.64 | ||||||
| Operating cashflow per share | $ | -0.06 | -0.34 | ||||||
| Capex per share | $ | 0.01 | 0.01 | ||||||
| FCF per share | $ | -0.07 | -0.35 | ||||||
| Free cash flow | $m | -6 | -61 | ||||||
| Net debt | $m | -138 | -136 | ||||||
| Book value equity | $m | 35 | 72 | ||||||
| Book value per share | $ | 0.42 | 3.72 | ||||||
| Number of shares | m | 83.59 | 19.4 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 21.23 | 10.36 | ||||||
| P/S LTM | x | 17.11 | 11.69 | ||||||
| P/FCF LTM | x | -135.93 | -12.22 | ||||||
| EV/EBITDA LTM | x | -18.46 | -30.18 | ||||||
| EV/Sales LTM | x | 14.13 | -1.57 | ||||||
| Earnings Yield LTM | % | -4.68% | -2.11% | ||||||
| FCF Yield | % | -0.74% | -8.18% | ||||||
| Quality | |||||||||
| ROE | % | -99.33% | -117.24% | ||||||
| ROIC | % | -42.09% | -34.65% | ||||||
| Operating margin | % | -95.92% | -78.98% | ||||||
| Gross margin | % | +96.48% | +70.69% | ||||||
| FCF/Sales | % | -12.59% | -107.26% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +589.88% | +910.28% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.79 | -9.72 | ||||||
| Net Debt/EBITDA | x | 3.90 | 4.80 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | 0.00% | +8.79% | ||||||
| Net debt/Equity | x | -3.90 | -1.88 | ||||||
| Gross debt/equity | x | 0.20 | 0.09 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to crafting immunotherapies aimed at strengthening the immune systems of cancer patients. A key part of their pipeline is XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody that is currently undergoing Phase 1/2 clinical trials for various solid tumors. The company also develops a range of cytokine programs, including XTX202 (a modified IL-2), XTX301 (an IL-12 product candidate), and XTX401 (an IL-15 product candidate). These cytokine therapies are ingeniously engineered with a protein domain that keeps them inactive until proteases specific to the tumor microenvironment (TME) cleave this mask, thereby initiating their therapeutic activity. Xilio Therapeutics, Inc. was founded in 2016 and is based in Waltham, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to crafting immunotherapies aimed at strengthening the immune systems of cancer patients. A key part of their pipeline is XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody that is currently undergoing Phase 1/2 clinical trials for various solid tumors. The company also develops a range of cytokine programs, including XTX202 (a modified IL-2), XTX301 (an IL-12 product candidate), and XTX401 (an IL-15 product candidate). These cytokine therapies are ingeniously engineered with a protein domain that keeps them inactive until proteases specific to the tumor microenvironment (TME) cleave this mask, thereby initiating their therapeutic activity. Xilio Therapeutics, Inc. was founded in 2016 and is based in Waltham, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free